Cibinqo (abrocitinib) / Pfizer, Glenmark - LARVOL DELTA

The Measurement and Management of Fatigue in Atopic Dermatitis: A Scoping Review of Methodologies and Interventions (AAD 2026) - "The anti-IL-4/13 antibody dupilumab has been shown in multiple RCTs and real-world studies to significantly improve sleep disturbance. JAK inhibitors, such as abrocitinib and upadacitinib, have been shown to improve both sleep and, explicitly, fatigue... A robust set of validated tools now exists to measure fatigue and sleep in AD, and these are increasingly being used in clinical trials. The evidence consistently shows that effective treatment of AD with both systemic and supportive therapies leads to significant improvements in sleep and fatigue. The management of fatigue should be considered a key, measurable goal in the treatment of atopic dermatitis."

Review • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Fatigue • Immunology • Sleep Disorder • IL4

Efficacy of abrocitinib therapy in daily practice: clinician- and patient-reported outcomes in a heterogeneous TREATgermany registry cohort using AHEAD criteria (AAD 2026) - "Combined moderate treatment targets were met by 96.2% achieving at least one CRO and one PRO after 3 months, with 72.4% maintaining this at 6 months. These findings highlight the robust efficacy of abrocitinib in improving both CRO and PRO, providing a strong basis for its use in a heterogeneous patient population."

Clinical • Heterogeneity • Patient reported outcomes • Asthma • Atopic Dermatitis • Cardiovascular • CNS Disorders • Depression • Dermatitis • Hypertension • Immunology • Inflammation • Respiratory Diseases

Therapeutic Advances in Head and Neck Dermatitis (HND): A Clinical Update (AAD 2026) - " Selective JAK1 inhibitors, including upadacitinib and abrocitinib, achieve rapid and sustained clearance in dupilumab-refractory cases, while topical delgocitinib and roxolitinib have shown benefits without local adverse effects. IL-13 antagonists such as tralokinumab and lebrikizumab provided head-to-neck symptomatic and quality-of-life improvement in patients unresponsive to dupilumab or JAK inhibitors, with a favorable safety profile...Topical agents like ketoconazole and ciclopirox showed good tolerability and clinical improvement in mild cases. Oral itraconazole, while favored for its lipophilic properties and ability to reduce Malassezia-specific IgE, was often followed by relapse upon discontinuation... HND represents a distinct, treatment-resistant AD phenotype requiring strategic multimodal care. Immunomodulators and antifungal therapies, often combined with topical agents, offer promising results, though larger long-term trials are needed to define optimal..."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13

Application of real-world effectiveness outcomes of abrocitinib for atopic dermatitis to minimal disease activity criteria: a retrospective multicenter analysis of week 16 data (AAD 2026) - "In this real-world cohort, most patients achieved at least one clinician-reported outcome, with acceptable short-term safety. Limitations include retrospective design, small sample size, and incomplete documentation of some patient-reported outcomes."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Immunology • Infectious Disease • Neutropenia • Pruritus • Respiratory Diseases

Application of real-world effectiveness outcomes of abrocitinib for atopic dermatitis to Canadian treat-to-target criteria: a retrospective multicenter analysis of week 16 data (AAD 2026) - "These real-world findings show most patients achieved Canadian T2T goals with abrocitinib at weeks 16±6. Limitations include retrospective design, small sample size, and incomplete POEM documentation."

Real-world • Real-world effectiveness • Real-world evidence • Retrospective data • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Hematological Disorders • Hypertriglyceridemia • Immunology • Infectious Disease • Neutropenia • Pruritus • Respiratory Diseases

Enhanced Pruritus Relief with JAK Inhibitors Over Cytokine Inhibitors in Atopic Dermatitis: A Real-World Cohort Analysis (AAD 2026) - "This retrospective cohort study used the TriNetX global health research network to compare pruritus outcomes in AD patients treated with Janus kinase (JAK) inhibitors (abrocitinib or upadacitinib) versus cytokine inhibitors (dupilumab or tralokinumab). The more targeted mechanisms of cytokine inhibitors may limit pruritus modulation. Given their superior itch relief, JAK inhibitors should be considered for patients with severe pruritus."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13 • IL4

Reassessing Long-Term Safety and Efficacy of Topical and Systemic Therapies in Atopic Dermatitis: An Updated Comparative Review (AAD 2026) - "Topical agents such as high-potency corticosteroids, phosphodiesterase-4 inhibitors, tacrolimus, ruxolitinib, mucopolysaccharide polysulfate cream, and tapinarof cream were found to be effective in improving skin lesions and pruritus in mild-to-moderate AD...Biologics such as dupilumab, lebrikizumab, tralokinumab, and nemolizumab, as well as JAK inhibitors including abrocitinib and upadacitinib, consistently improved EASI scores and overall disease severity. Despite these advances, the limited number of robust comparative studies and standardized criteria for transitioning between treatment classes continues to limit evidence-based decision-making. In the absence of large-scale clinical trials, network meta-analyses and expert consensus panels could be utilized to clarify long-term safety, refine sequencing strategies, and enhance the generalizability of treatment recommendations."

Clinical • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

Using Statistical Modeling to Predict Abrocitinib Response After Early Dose Escalation (AAD 2026) - P3 | "Early dose escalation from abrocitinib 100 to 200 mg improved patients’ likelihood of achieving established and stringent disease control endpoints at Week 12."

Atopic Dermatitis • Dermatitis • Immunology • Pruritus

Treatment Earlier in Atopic Dermatitis Disease Duration Improves Patient Response to Abrocitinib (AAD 2026) - "Positive trends showed that patients with shorter AD duration clinically benefited from abrocitinib 200 mg. Treatment responses with abrocitinib 100 mg were consistent between duration cohorts."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • JAK1

Tailoring Treatment With Abrocitinib: Personalized Treatment Approaches Used in the JADE REAL Study (AAD 2026) - P | "This analysis demonstrates the benefits of having flexibility to increase or decrease abrocitinib doses in patients with moderate-to-severe AD and simulates real-world treatment patterns to address patients’ individual needs"

Atopic Dermatitis • Dermatitis • Immunology

Higher Health Care Resource Utilization Before Abrocitinib Initiation Among Later-Line Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis (AAD 2026) - "Substantial outpatient and pharmacy use occurred prior to abrocitinib initiation, particularly among later-line users. These findings highlight the need for treatment sequencing strategies and approaches to reduce the health care burden associated with management of M2S AD."

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The Association between Total IgE and Treatment Efficacy in Atopic Dermatitis: A Systematic Review (AAD 2026) - " A total of 59 studies assessing 11 therapeutic agents met criteria: dupilumab, tralokinumab, lebrikizumab, ligelizumab, IVIG, azathioprine, abrocitinib, omalizumab, cyclosporine, upatacitinib, and topical corticosteroids. Decreases in total IgE generally reflect treatment efficacy with notable exceptions. The inconsistent impact of successful AD treatments on total IgE challenges the utility of this value as a biomarker for treatment efficacy."

Clinical • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-Term Efficacy of Abrocitinib Down-Titration in Patients With Moderate-to-Severe Atopic Dermatitis (AAD 2026) - P3 | "For patients achieving disease suppression following abrocitinib induction, maintenance on a lower dose—with the option of rescue therapy for breakthrough activity—could be an effective management strategy."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Early persistence of abrocitinib use in biologic-naive and biologic-exposed adult patients with moderate to severe atopic dermatitis: a real world study (AAD 2026) - "Characteristics were summarized for biologic-exposed (≥1 fill of Dupilumab, Lebrikizumab, Nemolizumab, or Tralokinumab) and biologic-naïve patients prior to abrocitinib initiation. Both biologic-naïve and biologic-exposed patients demonstrated early persistence of abrocitinib in both adolescents and adults, supporting its tolerability and perceived efficacy both as initial and subsequent advanced treatment for M2S AD."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Clinical Characteristics of JAK Inhibitor-Associated Acne: A Retrospective Review (AAD 2026) - " We retrospectively reviewed charts of patients at Mount Sinai Dermatology prescribed oral JAK inhibitors (abrocitinib, upadacitinib, tofacitinib, ritlecitinib, or baricitinib) with a documented diagnosis of acne...The most frequently used acne treatments were topical tretinoin (n=20), clindamycin (n=18), and oral doxycycline (n=18)... As JAK inhibitor prescriptions rise, acne is an increasingly observed dermatologic adverse event. Defining risk profiles and timing may enhance patient counseling, clinical monitoring, and therapeutic decision-making."

Retrospective data • Review • Acne Vulgaris • Immunology

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: Results from a 12-week real-world multicentre retrospective study in India (AAD 2026) - "Our study highlights the rapid onset of action of abrocitinib, with significant improvements in skin clearance and symptom relief observed throughout the study duration. Safety profile was also consistent with prior evidence, with no severe adverse events or new safety concerns reported."

Real-world • Real-world evidence • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Effectiveness of Abrocitinib in Cyclosporine-Resistant Atopic Dermatitis: A Real-World Experience from the Indian Subcontinent (AAD 2026) - "Prior therapies included cyclosporine, methotrexate, and systemic corticosteroids. Conclusion Abrocitinib showed rapid, sustained improvement in AD severity and pruritus among Indian patients unresponsive to cyclosporine. It was generally well tolerated and represents a promising therapeutic option, including in selected adolescents."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Disorders • Immunology • Inflammation • Pruritus • Thrombocytopenia

Abrocitinib attenuates itch-related gene expression in atopic dermatitis: Evidence from lesional and peri-lesional skin organ culture and skin biopsies from atopic dermatitis patients (AAD 2026) - P2a | "Several genes, including OSMR, IL4R, and F2RL1, showed similar regulation by abro ex vivo and in vivo, while other genes related to IL-4, IL-13, IL-31, and mast cell/histamine signaling were differentially regulated only in the JADE MOA trial. These findings align with the clinical responses to abro, further demonstrating that abro reduces itch-related gene expression and predominantly modulates IL-4, IL-13, IL-31, and mast cell/histamine pathways."

Biopsy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CD123 • IL13 • IL4R • IL4R • OSMR

Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Greater Achievement of Minimal Disease Activity With Abrocitinib Versus Dupilumab: An AHEAD Treat-to-Target Analysis of Patients With Moderate-to-Severe Atopic Dermatitis (AAD 2026) - P2b, P3, P3b | "Patients receiving abrocitinib monotherapy or combination therapy achieved MDA; abrocitinib combination therapy resulted in higher rates of MDA than dupilumab."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Treatment of Generalized Granuloma Annulare with JAK Inhibitors: A Systematic Review (AAD 2026) - "Agents included tofacitinib (n=28), baricitinib (n=11), upadacitinib (n=10), abrocitinib (n=1), and ruxolitinib (n=1). JAK inhibitors demonstrate consistent efficacy and manageable safety in refractory GGA, supporting their role as a promising targeted therapy. Current evidence is limited to small studies with moderate to high risk of bias. Larger controlled trials are needed to establish long-term efficacy, durability, and optimal dosing."

Review • Dyslipidemia • Herpes Zoster • Infectious Disease • Rare Diseases • Varicella Zoster

Comparative Safety Profiling of Four JAK Inhibitors in Real-World Data: FAERS Disproportionality and Time-to-Event Analysis (AAD 2026) - " FDA Adverse Event Reporting System (FAERS) reports from January 2022 to March 2025 for upadacitinib (n=47,075), abrocitinib (n=2,575), baricitinib (n=3,278), and tofacitinib (n=50,211) were analyzed. Differential AE profiles among JAK inhibitors were observed, with selective JAK1 inhibitors (upadacitinib, abrocitinib) generally exhibiting lower infection, thromboembolic, and malignancy risks compared with baricitinib. Time-to-onset analysis highlights early AE occurrence followed by decline, providing insight for clinical monitoring."

Clinical • Real-world • Real-world evidence • Acne Vulgaris • Cardiovascular • Cataract • Gastroenterology • Gastrointestinal Disorder • Hepatology • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Musculoskeletal Diseases • Ophthalmology • Thrombosis • Ulcerative Colitis • Varicella Zoster

Efficacy and Safety of Abrocitinib in Patients With Atopic Dermatitis Who Have Skin of Color: A Post Hoc Analysis of JADE EXTEND (AAD 2026) - P3 | "Abrocitinib demonstrated long-term effectiveness and tolerability in patients with SoC and findings were consistent with previous reports."

Clinical • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Upadacitinib Leads in Efficacy: Bayesian Network Meta-Analysis of Four JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis (AAD 2026) - "Among JAK inhibitors for moderate-to-severe AD, upadacitinib 30mg and 15mg showed the most consistent and robust efficacy, followed by abrocitinib 200mg. Ivarmacitinib 8mg offered intermediate benefit, while baricitinib showed modest effects. These findings highlight upadacitinib 30mg as the most clinically impactful regimen, informing treatment choice and future comparative studies."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab demonstrated consistent effectiveness in patients with and without prior exposure to advanced systemic therapies: interim analysis of the non-interventional study AD-LIFE (AAD 2026) - "Patients were considered pretreated with advanced systemic therapies [AdvST] if they had received an approved JAKi (baricitinib, abrocitinib, upadacitinib) or a biologic (tralokinumab, dupilumab). Adverse drug reactions under LEB (in this interim analysis) were consistent with those in clinical trials. No new safety signals were observed."

Clinical • Metastases • Observational data • Atopic Dermatitis • Dermatitis • Immunology • Pruritus